enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Pertuzumab - Wikipedia

   en.wikipedia.org/wiki/Pertuzumab

   Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...

3. Pertuzumab/trastuzumab/hyaluronidase - Wikipedia

   en.wikipedia.org/wiki/Pertuzumab/trastuzumab/...

   The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...

4. Trastuzumab deruxtecan - Wikipedia

   en.wikipedia.org/wiki/Trastuzumab_deruxtecan

   Trastuzumab deruxtecan was approved for medical use in the United States in December 2019, [12] in Japan in March 2020, [14] in the European Union in January 2021, [8] [10] and in Australia in October 2021. [1] It is the first approved therapy by the US Food and Drug Administration (FDA) targeted to people with the HER2-low breast cancer ...

5. FDA Grants Genentech's Perjeta Regimen Priority Review for ...

   www.aol.com/2013/07/02/fda-grants-genentechs...

   For premium support please call: 800-290-4726 more ways to reach us

6. FDA Advisory Committee Recommends Accelerated Approval of ...

   www.aol.com/news/2013-09-12-fda-advisory...

   FDA Advisory Committee Recommends Accelerated Approval of Genentech's Perjeta for Neoadjuvant Use in HER2-Positive Early Stage Breast Cancer The FDA Will Make a Final Decision by October 31 The ...

7. FDA Issues Urgent Warning on Dangers of Common Dog Medication

   www.aol.com/fda-issues-urgent-warning-dangers...

   The United States Food and Drugs Administration is warning pet owners about a common medication given to pets to treat arthritis. The F.D.A. now says that the drug Librela may be associated with ...

8. AOL Mail

   mail.aol.com

   Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!

9. Mogamulizumab - Wikipedia

   en.wikipedia.org/wiki/Mogamulizumab

   Mogamulizumab was approved for medical use in Japan in 2012. It was approved for medical use in the United States and the European Union in 2018. [5] [6] It was approved for medical use in Canada in 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [9]